

**Lantheus Medical Imaging to Host Second Quarter 2013 Conference Call on August 8, 2013 at 4:00 p.m. Eastern Time**

August 1, 2013 8:34 AM ET

**FOR IMMEDIATE RELEASE**

**CONTACTS:**

Linda Lennox  
978-671-8854

Meara Murphy  
978-671-8508

**Lantheus Medical Imaging to Host Second Quarter 2013 Conference Call  
on August 8, 2013 at 4:00 p.m. Eastern Time**

**N. Billerica, Mass., August 1, 2013** – Lantheus Medical Imaging, Inc. (“Lantheus”) today announced that it will host a conference call at 4:00 p.m. ET on Thursday, August 8, 2013, to discuss its financial and operating results for the second quarter of 2013.

To access the live conference call via telephone, please dial 1-877-261-8990 (U.S. callers) or 1-847-619-6441 (international callers) and provide passcode 35424187. A live audio webcast of the call also will be available on the homepage of the Company’s website at [www.lantheus.com](http://www.lantheus.com).

A replay of the telephone conference call and audio webcast will be available from approximately 6:30 p.m. ET on August 8, 2013 through midnight on August 22, 2013. To access a replay of the conference call, dial 1-888-843-7419 (U.S. callers) or 1-630-652-3042 (international callers), and provide passcode 35424187.

**About Lantheus Medical Imaging, Inc.**

Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The Company’s proven success in the field of diagnostic imaging provides a strong platform from which to bring forward breakthrough tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY<sup>®</sup> Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, TechnoLite<sup>®</sup> (Technetium Tc99m Generator), Cardiolite<sup>®</sup> (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has approximately 550 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit [www.lantheus.com](http://www.lantheus.com).

###